← Back to Clinical Trials
Recruiting NCT07083037

NCT07083037 Enhancing Preschool Children's Attention and Behaviour: Parent-Focused Program

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07083037
Status Recruiting
Phase
Sponsor McGill University
Condition Maternal Depression
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-02-01
Primary Completion 2027-07-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Building Regulation in Dual Generations (BRIDGE; DBT + Parenting)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-02-01 with a primary completion date of 2027-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the feasibility and efficacy of the Building Regulation in Dual Generations (BRIDGE) program for caregivers with significant mental health concerns and preschool and young children (3-7 years old) with elevated attention and/or behavior problems. The BRIDGE program focuses on supporting parental psychological distress and improving young children's self-regulation (SR), thereby reducing their attention and behavior problems. The long-term goal of this work is to improve family well-being and social-emotional development for young children by implementing an accessible and scalable dual-regulation program. The investigators will achieve this through the following key objectives: 1. Assess the feasibility and accessibility of BRIDGE for preschool and young children (3-7 years old) with significant attention and behavior programs through questionnaires asking about attendance, satisfaction, and unmet needs. 2. Examine the efficacy of BRIDGE compared to control group at improving maternal mental health and child attention and behavioral difficulties in young children (primary outcomes). The investigators will also examine parenting stress (secondary outcome). 3. Identify predictors of academic readiness skills in preschool and young children. The investigators hypothesize that an increase in parental and child emotion-regulation skills and reduced attention, as well as behavioral problems, will lead to increased pre-academic skills in children.

Eligibility Criteria

Inclusion Criteria: BRIDGE Therapy Group: Participants are deemed eligible for the BRIDGE therapy group if they meet the following criteria: 1. Above the age of 18. 2. Self-identify as a mother of a child between the age of 3-7 years old. 3. Currently living in Quebec, Ontario, or Manitoba 4. Fluency in English. 5. Mothers must have clinically significant symptoms of depression (mild to moderate on the Patient Health Questionnaire and indicate symptoms to "somewhat cause difficulties") currently affecting them. Participants also need to report symptoms of depression during pregnancy or shortly after birth. 6. Their child has attention and/or behavior problems (T-score \> 65 on the Child Behavior Checklist (CBCL) ADHD subscales) or confirmed attention and/or behavior problems through clinical interview. Control Group: Participants are deemed eligible for the Control group if they meet the following criteria: 1. Above the age of 18 2. Self-identify as a mother of a child between the age of 3-7 years old 3. Currently living in Quebec, Ontario, or Manitoba 4. Fluency in English or bilingual 5. Mothers must NOT have clinically significant symptoms of depression (mild to moderate on the Patient Health Questionnaire) 6. Their child DOES NOT have attention and/or behavior problems (T-score \> 65 on the Child Behavior Checklist (CBCL) ADHD subscales). Exclusion Criteria: BRIDGE Therapy Group: Participants were excluded if they A) did not meet the inclusion criteria listed above or B) were unable to attend the weekly BRIDGE group therapy sessions. Furthermore, eligible participants were invited to complete a semi-structured intake interview with principal investigator (PI) Dr. Tasmia Hai or a graduate student trainee under Dr. Hai's supervision, during which further questions about their mental health and child behavior were asked to ensure their eligibility. Based on the clinical suitability interview, participants may be excluded if they are deemed to be ineligible based on A) the mother's absence of clinically significant mental health symptoms, and/or B) the child's absence of attention and/or behavior problems. When relevant, participants may be identified to participate in the control group instead if eligibility is met. Control Group: Participants were excluded if they did not meet the inclusion criteria listed above. Furthermore, eligible participants were invited to complete a semi-structured intake interview with principal investigator (PI) Dr. Tasmia Hai, during which further questions about their mental health and child behavior were asked to ensure their eligibility. Based on the clinical suitability interview, participants may be excluded if they are deemed to be ineligible based on a) the mother's presence of clinically significant mental health symptoms, and/or B) the child's presence of attention and/or behavior problems. When relevant, participants may be identified to participate in the BRIDGE therapy group instead if eligibility is met.

Contact & Investigator

Central Contact

Tasmia Hai, PhD

✉ tasmia.hai@umanitoba.ca

📞 204-474- 8258

Frequently Asked Questions

Who can join the NCT07083037 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Maternal Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07083037 currently recruiting?

Yes, NCT07083037 is actively recruiting participants. Contact the research team at tasmia.hai@umanitoba.ca for enrollment information.

Where is the NCT07083037 trial being conducted?

This trial is being conducted at Winnipeg, Canada, Montreal, Canada.

Who is sponsoring the NCT07083037 clinical trial?

NCT07083037 is sponsored by McGill University. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology